Scientists have made a discovery that could change how we fight some of the most common and dangerous viral infections. Researchers at the University of Maryland, Baltimore County (UMBC) have identified a critical step that many enteroviruses use to take over human cells and multiply. This family of viruses includes polio, encephalitis, myocarditis, and the common cold.

The findings were published in the journal Nature Communications. They explain how these viruses hijack the cell’s own machinery to make copies of themselves. Experts say this work could eventually lead to a new class of antiviral drugs that work against many different enteroviruses at once.

What Are Enteroviruses and Why Should You Care?

Enteroviruses are a large group of viruses that infect millions of people worldwide every year. Most people know them as the cause of the common cold. But some enteroviruses cause much more serious illnesses.

Polio, which can cause paralysis, is an enterovirus. So are viruses that cause encephalitis, which is swelling of the brain, and myocarditis, which is inflammation of the heart muscle. Even some cases of hand, foot, and mouth disease in children come from enteroviruses.

For most healthy adults, a cold is just a nuisance. But for people with weakened immune systems, young children, and older adults, these viruses can be dangerous. There are currently no broad-spectrum antiviral drugs that can treat the entire enterovirus family. That is why this new research is so important.

How the Study Was Conducted

The study was led by Deepak Koirala, an associate professor of chemistry and biochemistry at UMBC. He worked with recent Ph.D. graduate Naba Krishna Das. Their team wanted to solve a long-standing mystery about how enteroviruses start replicating once they enter a human cell.

“My lab has been really motivated to understand how RNA viruses produce their proteins inside the cell and multiply their genome to make more virus particles,” Koirala said in a statement.

The researchers previously discovered a cloverleaf-shaped structure within the virus’s genetic material, called RNA. In this new study, they showed exactly how that cloverleaf structure recruits proteins that the virus needs to build its replication machinery.

To get these detailed images, the team used several advanced techniques. X-ray crystallography allowed them to see the cloverleaf RNA and a key protein called 3CD together in 3D. They also used isothermal titration calorimetry, which measures the heat released when molecules bind together. A third method called biolayer interferometry tracked how long molecules stayed attached by measuring changes in light interference.

The Key Discovery: A Molecular Switch

Enteroviruses carry very small RNA genomes. These tiny genomes have to do two jobs at the same time. The viral RNA must direct the production of viral proteins. At the same time, it must serve as the template for making new copies of the virus.

Most of the viral genome contains instructions for building structural proteins. But it also encodes several specialized proteins needed for replication. One of the most important is a fusion protein called 3CD.

This protein has two parts. The 3C portion cuts long chains of amino acids into the separate proteins the virus needs. The 3D portion acts as an RNA polymerase, which is an enzyme that copies viral RNA so the virus can reproduce. Human cells do not naturally contain this type of polymerase. That means the virus must supply its own version.

“We previously determined the structure of the RNA alone, and other groups determined the structure of 3C and 3D, but now we’ve captured the structure of the RNA and proteins together, so we know how they are interacting,” Koirala explained. “We found that it’s the 3C domain of 3CD that binds to the RNA in the viral genome, and then it recruits the other components, such as host protein PCBP2, to assemble the replication complex.”

The researchers also discovered that this molecular complex works like a switch. When 3CD is attached to the RNA, the virus copies its genome. When the protein detaches, the RNA becomes available for producing viral proteins instead. This switching mechanism is critical for the virus to survive and spread.

Settling a Scientific Debate

The experiments helped resolve an ongoing debate among scientists. The team showed that two full 3CD molecules, each carrying its own RNA polymerase, bind side by side on the viral RNA. Earlier research had proposed that the proteins formed a single fused pair instead.

Scientists still do not fully understand why two copies are required. But the new study provides a much clearer picture of how the replication process begins. This understanding is essential for designing drugs that can stop it.

Why This Discovery Could Lead to Better Antiviral Drugs

One of the most promising findings was how similar the mechanism appeared across all seven enteroviruses examined in the study. The viruses shared nearly identical RNA cloverleaf structures and binding behavior.

That level of similarity suggests the RNA structure is extremely important to viral survival. Significant mutations would likely disrupt replication. This makes the structure a potentially stable drug target across many enteroviruses.

Researchers say this raises the possibility of developing broad-spectrum antiviral drugs. These drugs could work against an entire family of viruses rather than just a single pathogen.

What Experts Say About the Future of Treatment

Scientists are already developing drugs that interfere with the 3C and 3D proteins. But the new findings reveal another possible strategy.

“Now we have another layer to test,” Koirala said. “What if we target the RNA, or the RNA-protein interface, so that we break the interaction? That is another opportunity. Now that we have high-resolution structures, you can precisely design drug molecules to target them.”

This approach could be more effective than current treatments. Many antiviral drugs target viral proteins, which can mutate and become resistant. Targeting the RNA structure or the interface between RNA and proteins may be harder for the virus to change.

Koirala says the study highlights how surprisingly sophisticated viruses can be despite their tiny genomes.

“Viruses are so, so clever. Their entire genome is equivalent to about one mRNA sequence in humans, yet they are so effective,” Koirala said. His latest work demonstrates “why we need to investigate this basic science — so that it can be translated into developing drugs targeting pathogens that cause so many harmful diseases.”

Practical Takeaways for Readers

While this research is still in the early stages, it has important implications for public health. Here is what you should know:

• No new drugs are available yet. This is basic science research. It will take years of additional testing before any new antiviral treatments reach patients.
• Prevention is still your best defense. Hand washing, avoiding close contact with sick people, and staying home when you are ill can reduce your risk of catching enteroviruses.
• Vaccines remain critical. The polio vaccine is a powerful tool that has nearly eliminated the disease worldwide. Staying up to date on recommended vaccines is important.
• Antiviral research is progressing. Scientists are learning more every year about how viruses work. This knowledge is the foundation for future treatments.
• Common colds are still viral infections. Antibiotics do not work against viruses. Rest, fluids, and over-the-counter symptom relief are the main treatments for now.

What This Means for the Bigger Picture

This study is a reminder that basic science matters. Understanding how viruses work at the molecular level is the first step toward developing new medicines. The discovery of this shared weak spot in enteroviruses could eventually lead to drugs that treat everything from the common cold to life-threatening heart and brain infections.

For now, the research gives scientists a clear target to aim at. With high-resolution structures now available, drug designers can begin working on molecules that might disrupt the virus’s replication process. If successful, these drugs could change how we treat viral infections for years to come.

The study was supported by the University of Maryland Baltimore County. The researchers note that their findings represent a significant step forward in understanding how these clever and dangerous viruses operate.

Source: ScienceDaily